Home › Results from Mercks Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine
 

Keywords :   


Results from Mercks Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine

2016-08-08 23:05:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in of results study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.04K-State researcher awarded $2.6 million to fight African swine fever
29.04Chairman Reinold Geiger Makes Offer To Take L\'Occitane Private
29.04FTC Fines Razer Over Misrepresented N95 Claims
29.04U by Kotex, Thinx and Walgreens Work to Fight Period Poverty
29.04US probes Ford hands-free driving tech after crashes
29.04Cattle markets are getting back on track
29.04JLR to Use Alkegens EV Battery Solutions
29.04Albany International Ceases Manufacturing in South Korea
More »